跳至主要内容
临床试验/NCT03728725
NCT03728725已完成不适用

Multicentre Clinical Trial to Assess the Performance of the Xpert MTB/XDR Assay for INH- and Second-line Resistance Detection

Foundation for Innovative New Diagnostics, Switzerland1 个研究点 分布在 1 个国家目标入组 710 人开始时间: 2019年7月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
710
试验地点
1
主要终点
Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for INH and ETH resistance detection

研究概览

简要总结

FIND and partners intend to address the need for a multi- and extensively drug-resistant tuberculosis (M/XDR-TB) diagnostic solution for patients in settings with a high burden of drug-resistant tuberculosis (DR-TB) though the development, evaluation and introduction of an Xpert MTB/XDR assay

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • • Age 18 years or above;
  • Symptoms suggesting pulmonary TB, i.e. persistent cough (generally ≥3 weeks or as per local definition of TB suspect), and at least one of the following:
  • Previously received >1 month of treatment for a prior TB episode or
  • Failing TB treatment with positive sputum smear or culture after ≥3 months of a standard TB treatment or
  • Had close contact with a known drug-resistant TB case or
  • Newly diagnosed with MDR-TB within the last 30 days or
  • Previously diagnosed with MDR-TB and failed TB treatment with positive sputum smear or culture after ≥3 months of a standard MDR-TB treatment regimen
  • Patients meeting the above criteria will be screened by Xpert MTB/RIF or Xpert MTB/RIF Ultra. TB patients meeting the following criteria will be included in the study:
  • A clear Mtb-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or Xpert MTB/RIF Ultra
  • Provision of informed consent;
  • Production of an adequate quantity (>3mL) of sputum

排除标准

  • Participants will be excluded from the study if informed consent is not provided.

结局指标

主要结局

Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for INH and ETH resistance detection

时间窗: Day 1

Sensitivity and specificity estimates for INH and ETH resistance detection

Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for fluoroquinolone resistance detection

时间窗: Day 1

Sensitivity and specificity estimates for fluoroquinolone resistance detection

Estimate the diagnostic accuracy of the Xpert MTB/XDR assay for second-line injectable resistance detection

时间窗: Day 1

Sensitivity and specificity estimates for second-line injectable resistance detection

次要结局

未报告次要终点

研究者

发起方
Foundation for Innovative New Diagnostics, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验